INHIBRX BIOSCIENCES, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
INHIBRX BIOSCIENCES, INC. (INBX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 3.60 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 3.59M shares, a 0.76% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 3.73M shares, a 2.47% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 188.00K shares, a 0.00% change year-over-year.
- INHIBRX BIOSCIENCES, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 3.56M shares, a 133.95% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 3.64M shares, a 1901.10% increase from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 182.00K shares, a 88.60% decline from fiscal 2023.
- INHIBRX BIOSCIENCES, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 1.60M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 3.60M shares 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | 3.59M shares 10-Q · filed 2026-05-14 | ||||
| 2025-12-31 | 3.64M shares 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | 3.73M shares 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | 188.00K shares 10-Q · filed 2025-08-13 | 3.79M shares 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | 3.56M shares 10-Q · filed 2026-05-14 | ||||
| 2024-12-31 | 182.00K shares 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | 3.64M shares 10-Q · filed 2025-11-14 | 243.00K shares 10-Q · filed 2025-11-14 | 910.00K shares 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | 188.00K shares 10-Q · filed 2024-08-13 | 366.00K shares 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | 1.52M shares 10-Q · filed 2025-05-14 | ||||
| 2023-12-31 | 1.60M shares 10-K · filed 2025-03-17 | ||||
| 2023-09-30 | 1.68M shares 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | 1.66M shares 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |